In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

• Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
• Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases   
• Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
• The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC 
   

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.